Medical Devices Reimbursement Market: as CMS opens its first full quarterly nomination cycle under the Transitional Coverage for Emerging Technologies pathway and grants eligibility to specific cardiac and continuous glucose monitoring devices, the multi-year gap between FDA market authorisation and Medicare national coverage that has long slowed device commercialisation is being tested in practice for the first time, so device manufacturers now have concrete evidence of which technology categories the pathway actually accelerates, shifting reimbursement strategy planning from theoretical policy anticipation to evidence-based positioning around a functioning programme.

The global medical devices reimbursement market size was USD 643.70 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period. Market revenue growth is driven by factors such as expedited coverage pathways narrowing the gap between FDA market authorisation and Medicare national coverage, global payer adoption of value-based device reimbursement frameworks, and expanding reimbursement documentation and identifier requirements creating new administrative and technology demand. The first driving factor is expedited coverage pathways, as CMS and comparable international payers establish structured mechanisms for accelerating national coverage decisions for breakthrough and emerging device technologies. Surgical and implantable devices account for a substantial share of total 2025 market revenue, reflecting the reimbursement complexity and claim value associated with the most clinically significant device categories. The second driving factor is global payer adoption of value-based device reimbursement frameworks, which tie payment more directly to documented clinical outcomes rather than device acquisition cost alone. The third driving factor is expanding reimbursement documentation and identifier requirements, as regulatory bodies increasingly mandate structured data supporting reimbursement transparency and planning. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single expedited coverage pathway designation converts a device's uncertain multi-year path to Medicare national coverage into a defined, time-bound review process, which lets a manufacturer's reimbursement and market access planning shift from open-ended policy uncertainty to a concrete pathway with a stated coverage decision timeline. Because the historical gap between FDA market authorisation and Medicare national coverage determination has often extended multiple years, creating a commercially difficult period where a device is legally marketable but not yet reimbursed at scale, a structured pathway that targets a coverage decision within a defined window after authorisation directly compresses this gap for the specific device categories the pathway covers. As a result, demand and revenue share are concentrating around device categories that successfully secure expedited pathway eligibility, and the forecast tilts toward manufacturers who can position their breakthrough device candidates for pathway nomination rather than those relying on the traditional, open-ended coverage determination timeline. For instance, in January 2026, the CMS Transitional Coverage for Emerging Technologies pathway opened its Q1 2026 quarterly nomination cycle, accepting up to five Breakthrough Device candidates per annual cycle, with three devices from cardiac monitoring and continuous glucose monitoring categories receiving TCET eligibility determination in this cycle specifically. These are some of the key factors driving revenue growth of the market.

Because most major public and private payers require prior authorisation for a substantial share of higher-cost device categories, the administrative burden of obtaining, documenting, and defending these authorisations adds real cost and delay to device access even where the underlying clinical case for use is well established.

Elevated claim denial and underpayment rates are a second constraint, since a meaningful share of submitted device claims across payer types are either denied outright or reimbursed below the provider's actual acquisition and procedure cost, creating cash flow uncertainty that affects both provider willingness to adopt newer, higher-cost device technologies and manufacturer revenue predictability.

DMEPOS supplier enrollment restrictions are a third constraint, since CMS's response to documented improper payment risk in certain durable medical equipment supplier categories has included enrollment moratoriums that, while addressing genuine fraud and billing integrity concerns, also constrain market access for new suppliers seeking to enter these device reimbursement categories.

These factors substantially limit medical devices reimbursement market growth over the forecast period.

The clearest driver of demand is expedited coverage pathways, as CMS and comparable international payers establish structured mechanisms for accelerating national coverage decisions for breakthrough and emerging device technologies. A device that is FDA-authorised but not yet nationally covered by Medicare occupies a commercially difficult middle ground where the manufacturer bears the cost of continued clinical evidence generation without the reimbursement scale that drives broad adoption, so a pathway that compresses this gap directly addresses one of the most consequential commercial risk periods in a device's lifecycle. Surgical and implantable devices account for a substantial share of total 2025 market revenue, and CMS's Transitional Coverage for Emerging Technologies pathway targets coverage decisions within six months of FDA market authorisation for eligible FDA-designated Breakthrough Devices. The effect on the market is that reimbursement timeline predictability is becoming a genuine competitive advantage for manufacturers whose devices qualify for expedited pathway designation. These are some of the key factors driving revenue growth of the market.

The second driver is global payer adoption of value-based device reimbursement frameworks, which tie payment more directly to documented clinical outcomes rather than device acquisition cost alone. A reimbursement structure based purely on device acquisition cost creates limited incentive for a manufacturer to invest in generating the kind of long-term outcome evidence that actually demonstrates a device's value, so value-based frameworks that link reimbursement level to documented clinical outcomes realign manufacturer incentives toward evidence generation that benefits both payers and patients. The effect on the market is that manufacturers increasingly need comprehensive post-market clinical evidence generation capability as a core reimbursement strategy component, not simply a regulatory compliance activity separate from commercial planning. These are some of the key factors driving revenue growth of the market.

CMS's TCET pathway granted eligibility to three devices from cardiac monitoring and continuous glucose monitoring categories in its Q1 2026 nomination cycle alone. The multi-year gap between FDA authorisation and Medicare coverage is now being tested with concrete devices, not theoretical policy design.

The third driver is expanding reimbursement documentation and identifier requirements, as regulatory bodies increasingly mandate structured data supporting reimbursement transparency and planning across jurisdictions. A reimbursement system that lacks standardised, structured device identifier data makes it genuinely difficult for payers, providers, and manufacturers to reliably link a specific device to its associated claims and outcomes data, so mandatory reimbursement-linked device identifier registration directly addresses a data infrastructure gap that has historically complicated value-based reimbursement adoption. In April 2025, the European Commission published updated EU MDR implementation guidance on economic operator obligations under EUDAMED, requiring manufacturers to register reimbursement-linked device identifiers by the third quarter of 2025. The effect on the market is that reimbursement documentation compliance is becoming a distinct administrative and technology investment area for device manufacturers, separate from but connected to broader regulatory compliance activity. These are some of the key factors driving revenue growth of the market.

However, the medical devices reimbursement market faces severe adoption constraints from persistent prior authorisation administrative burden across major payers and elevated claim denial and underpayment rates affecting device manufacturer and provider cash flow.

Because most major public and private payers require prior authorisation for a substantial share of higher-cost device categories, the administrative burden of obtaining, documenting, and defending these authorisations adds real cost and delay to device access even where the underlying clinical case for use is well established, a burden that expedited pathways like TCET only partially address for specifically eligible breakthrough devices.

Elevated claim denial and underpayment rates compound this, since a meaningful share of submitted device claims across payer types are either denied outright or reimbursed below the provider's actual acquisition and procedure cost, creating cash flow uncertainty that affects both provider willingness to adopt newer, higher-cost device technologies and manufacturer revenue predictability.

DMEPOS supplier enrollment restrictions are the third constraint, since CMS's February 2025 six-month moratorium on Medicare enrollment for certain DMEPOS supplier categories, issued in response to USD 2.27 billion in identified improper payments, addresses genuine fraud and billing integrity concerns but also constrains market access for new suppliers seeking to enter these device reimbursement categories.

These factors substantially limit medical devices reimbursement market growth over the forecast period.

Based on device type, the global medical devices reimbursement market is segmented into diagnostic imaging, surgical and implantable, therapeutic, and durable medical equipment devices. Surgical and implantable devices hold the largest revenue share, because these devices carry the highest per-unit reimbursement value and the most complex claim documentation requirements of any device category, which suits a market where claim value concentration favours the most clinically significant device types. Diagnostic imaging devices remain a substantial and closely sized second category given the high volume of imaging procedures across nearly every care setting. Durable medical equipment is expected to register the fastest revenue growth rate in the global medical devices reimbursement market over the forecast period, driven by expanding home health and remote monitoring device reimbursement policy, including the CGM devices receiving TCET pathway eligibility.

Based on payer type, the global medical devices reimbursement market is segmented into public payers, private health insurance, and out-of-pocket payment. Public payers, including Medicare, Medicaid, and comparable national health systems, hold the largest revenue share, because government healthcare programmes cover the largest single beneficiary population across most major markets globally, which ties directly back to the expedited coverage pathway policy described in the market's primary demand driver. Private health insurance is expected to register a significant revenue growth rate in the global medical devices reimbursement market over the forecast period, driven by expanding value-based contracting arrangements between device manufacturers and private payers.

Based on claim type, the global medical devices reimbursement market is segmented into paid, underpaid, and denied and appealed claims. Paid claims hold the largest revenue share, reflecting the majority of submitted device claims that clear payer review and receive reimbursement at the submitted or negotiated rate. Denied and appealed claims are expected to register the fastest revenue growth rate in the global medical devices reimbursement market over the forecast period as claim volume grows overall, driven by increasing claim complexity for newer device categories and expanding prior authorisation requirements across major payers.

Based on regional analysis, the medical devices reimbursement market in North America accounted for largest revenue share in 2025. The United States leads because CMS's TCET pathway and the scale of Medicare's device-covered beneficiary population create the deepest and most structurally significant reimbursement market globally, and because UnitedHealth Group, Elevance Health, and Aetna all maintain their primary commercial presence in the US market. CMS's February 2025 DMEPOS enrollment moratorium, issued in response to USD 2.27 billion in identified improper payments, specifically reflects the scale of US device claims processing activity. The concentration of CMS coverage policy development in the country also means new reimbursement pathway innovations are typically established in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. The European Commission's April 2025 updated EU MDR implementation guidance on EUDAMED economic operator obligations specifically targets reimbursement-linked device identifier registration across the region. The result is steady rather than rapid growth, shaped more by national health system budget cycles than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent two of the largest national markets within the region, driven by expanding national health insurance coverage and rising device reimbursement policy sophistication. The region's rapidly expanding insured population leaves considerably more room for growth than in the already reimbursement-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding public and private payer device coverage driving early reimbursement market growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the medical device components that Latin American manufacturers and distributors depend on, an effect expected to run through 2026 that indirectly raises device acquisition costs feeding into regional reimbursement claim values beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding national health insurance programme and the UAE's regional healthcare investment hub position represent the primary growth centres for medical devices reimbursement market development. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the payer infrastructure needed to support sophisticated device reimbursement frameworks at scale.